The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia.

Antineoplastic Agents / pharmacology Autophagy / drug effects Cell Line, Tumor Chemotaxis / drug effects Cytarabine / pharmacology Drug Discovery Drug Resistance, Neoplasm / drug effects Humans Ligands Mitochondrial Proteins / antagonists & inhibitors Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology Recurrence

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
07 2019
Historique:
received: 18 12 2018
accepted: 01 04 2019
pubmed: 24 4 2019
medline: 24 12 2019
entrez: 24 4 2019
Statut: ppublish

Résumé

Disease relapse in B-cell acute lymphoblastic leukemia (ALL), either due to development of acquired resistance after therapy or because of de novo resistance, remains a therapeutic challenge. In the present study, we have developed a cytarabine (Ara-C)-resistant REH cell line (REH/Ara-C) as a chemoresistance model. REH/Ara-C 1) was not crossresistant to vincristine or methotrexate; 2) showed a similar proliferation rate and cell surface marker expression as parental REH; 3) demonstrated decreased chemotaxis toward bone marrow stromal cells; and 4) expressed higher transcript levels of cytidine deaminase (

Identifiants

DOI: 10.1124/jpet.118.255984 PMID: 31010844 PMC: PMC6538890
pubmed: 31010844
pii: jpet.118.255984
doi: 10.1124/jpet.118.255984
pmc: PMC6538890
doi:

Substances chimiques

Antineoplastic Agents 0
CISD1 protein, human 0
Ligands 0
Mitochondrial Proteins 0
Cytarabine 04079A1RDZ

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-34

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM109098
Pays : United States
Organisme : NCRR NIH HHS
ID : P20 RR016440
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121322
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103434
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM103488
Pays : United States
Organisme : NIH HHS
ID : S10 OD016165
Pays : United States

Informations de copyright

Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Références

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 15;945-946:141-6
pubmed: 24334225
Pharmacogenomics. 2009 Oct;10(10):1657-74
pubmed: 19842938
Hum Genomics. 2011 Oct;5(6):709-17
pubmed: 22155609
Leuk Res. 1998 Jul;22(7):619-24
pubmed: 9680112
Int J Mol Sci. 2015 Nov 13;16(11):27313-26
pubmed: 26580606
Cancer Res. 2013 Jan 1;73(1):3-7
pubmed: 23288916
Bioorg Med Chem Lett. 2011 Sep 15;21(18):5498-501
pubmed: 21782425
Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E252-60
pubmed: 14570702
Leukemia. 2014 Apr;28(4):739-48
pubmed: 23892718
Cancer Res. 1986 Mar;46(3):1079-83
pubmed: 3484676
Leukemia. 2010 Apr;24(4):813-20
pubmed: 20111071
Blood. 1995 Nov 15;86(10):3861-8
pubmed: 7579354
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biochim Biophys Acta. 2015 Jun;1853(6):1294-315
pubmed: 25448035
J Vis Exp. 2016 Feb 09;(108):e53645
pubmed: 26891147
Bioorg Med Chem Lett. 2010 Feb 1;20(3):819-23
pubmed: 20064719
Am J Cancer Res. 2017 Dec 01;7(12):2395-2405
pubmed: 29312795
Oncogene. 2011 Apr 21;30(16):1855-67
pubmed: 21151168
Antioxid Redox Signal. 2019 Mar 10;30(8):1083-1095
pubmed: 29463105
Exp Hematol. 2016 Jan;44(1):50-9.e1-2
pubmed: 26407636
Leuk Res. 2018 Sep;72:59-66
pubmed: 30103201
J Clin Oncol. 2013 Jul 20;31(21):2736-42
pubmed: 23775972
Mitochondrion. 2013 May;13(3):199-208
pubmed: 22846431
Blood. 1997 Jul 1;90(1):346-53
pubmed: 9207471
Leuk Lymphoma. 1998 Oct;31(3-4):405-9
pubmed: 9869205
Exp Cell Res. 2014 Aug 1;326(1):90-102
pubmed: 24907655
Cell Cycle. 2012 Nov 15;11(22):4174-80
pubmed: 23070475
Nat Med. 2017 Oct;23(10):1234-1240
pubmed: 28920959
Oncotarget. 2016 Apr 26;7(17):23439-53
pubmed: 27015556
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14676-81
pubmed: 23959881
Science. 2008 Dec 19;322(5909):1861-5
pubmed: 19095944
Br J Haematol. 2000 Sep;110(3):563-72
pubmed: 10997965
Anticancer Res. 2015 Oct;35(10):5667-70
pubmed: 26408741
Leuk Res. 2001 Oct;25(10):901-7
pubmed: 11532524
Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3698-703
pubmed: 25762074
Cell Death Differ. 2009 Jul;16(7):1018-29
pubmed: 19390558
Cancer Res. 2008 Apr 1;68(7):2349-57
pubmed: 18381442
Blood. 1997 Oct 1;90(7):2723-9
pubmed: 9326239
Blood. 2010 Jun 10;115(23):4657-63
pubmed: 20304809
Blood. 2003 Dec 15;102(13):4541-6
pubmed: 12920041
J Cell Biol. 2013 Jan 21;200(2):163-72
pubmed: 23319602
Lancet. 1991 Aug 17;338(8764):399-403
pubmed: 1678081
Autophagy. 2009 Jul;5(5):727-8
pubmed: 19363300
Biochim Biophys Acta. 2011 Jun;1807(6):735-45
pubmed: 21453675
Blood Cells Mol Dis. 2015 Oct;55(3):220-7
pubmed: 26227851
Front Neurosci. 2017 Feb 16;11:78
pubmed: 28261054
Blood. 2000 Sep 1;96(5):1926-32
pubmed: 10961896
Mol Cancer Res. 2016 Oct;14(10):909-919
pubmed: 27358112

Auteurs

Werner J Geldenhuys (WJ)

Department of Pharmaceutical Sciences, School of Pharmacy (W.J.G.), Department of Microbiology, Immunology and Cell Biology, School of Medicine (R.R.N., K.H.M., L.F.G.), Robert C. Byrd Health Sciences Center (W.J.G., R.R.N., D.P., K.H.M., L.F.G.), and WVU Cancer Institute (W.J.G., K.H.M., L.F.G.), West Virginia University, Morgantown, West Virginia.

Rajesh R Nair (RR)

Department of Pharmaceutical Sciences, School of Pharmacy (W.J.G.), Department of Microbiology, Immunology and Cell Biology, School of Medicine (R.R.N., K.H.M., L.F.G.), Robert C. Byrd Health Sciences Center (W.J.G., R.R.N., D.P., K.H.M., L.F.G.), and WVU Cancer Institute (W.J.G., K.H.M., L.F.G.), West Virginia University, Morgantown, West Virginia.

Debbie Piktel (D)

Department of Pharmaceutical Sciences, School of Pharmacy (W.J.G.), Department of Microbiology, Immunology and Cell Biology, School of Medicine (R.R.N., K.H.M., L.F.G.), Robert C. Byrd Health Sciences Center (W.J.G., R.R.N., D.P., K.H.M., L.F.G.), and WVU Cancer Institute (W.J.G., K.H.M., L.F.G.), West Virginia University, Morgantown, West Virginia.

Karen H Martin (KH)

Department of Pharmaceutical Sciences, School of Pharmacy (W.J.G.), Department of Microbiology, Immunology and Cell Biology, School of Medicine (R.R.N., K.H.M., L.F.G.), Robert C. Byrd Health Sciences Center (W.J.G., R.R.N., D.P., K.H.M., L.F.G.), and WVU Cancer Institute (W.J.G., K.H.M., L.F.G.), West Virginia University, Morgantown, West Virginia.

Laura F Gibson (LF)

Department of Pharmaceutical Sciences, School of Pharmacy (W.J.G.), Department of Microbiology, Immunology and Cell Biology, School of Medicine (R.R.N., K.H.M., L.F.G.), Robert C. Byrd Health Sciences Center (W.J.G., R.R.N., D.P., K.H.M., L.F.G.), and WVU Cancer Institute (W.J.G., K.H.M., L.F.G.), West Virginia University, Morgantown, West Virginia lgibson@hsc.wvu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Autophagie › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Mouvement › Locomotion › Taxie › Chimiotaxie › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Cytarabine › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines mitochondriales › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › The MitoNEET Ligand NL-1 Mediates Antileukemic...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › The MitoNEET Ligand NL-1 Mediates Antileukemic...